Everand Logo

Welcome to Everand!

  • STAT

    Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

    What qualifies as a "cabal"? Will the CRISPR patent fight outlive us all? We get into those questions and more on the latest episode of "The Readout LOUD." Listen now:
    by Damian Garde and Adam Feuerstein Jun 27, 2019 1 minute

    Can Botox make Big Pharma attractive? What qualifies as a “cabal”? And will the CRISPR patent fight outlive us all?

    We discuss all

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

    Related Books & Audiobooks